News | Oncology Related Products | December 03, 2024

Data shows CancerIQ Reach closes gap between eligibility and participation in payer-supported, standard and supplemental screenings, leads to early cancer diagnoses and promotes health system loyalty.


Nov. 25, 2024 — CancerIQ has launched a new patient acquisition solution for imaging and oncology, CancerIQ Reach.The new solution ushers in a new era for population-based, personalized cancer prevention and early detection.

CancerIQ Reach is a campaign-based marketing outreach solution that helps healthcare providers efficiently and accurately identify individuals in their communities with elevated cancer risk and motivate them to take action within the health system. It requires little to no IT lift or changes to existing workflows, and was developed based on CancerIQ's experience working with patients and providers around the country.

"CancerIQ's mission is to help every patient get ahead of cancer, but we recognize that precision prevention for all is a long-range goal — and there are high-risk patients in our communities who can't afford to wait, " said Feyi Ayodele, co-founder and CEO of CancerIQ. "CancerIQ Reach answers that urgent call, enabling health systems to take a precision approach to outreach and drive high-risk patients directly to the service lines that will support their care needs today, not someday in the future."

CancerIQ Reach includes population segmentation tools and multichannel marketing toolkits that make it easy to engage target populations in online cancer risk assessment using personal and family medical history, as well as lifestyle factors; educate them about their risk and options for early detection; and drive them to follow payer-supported, standard and supplemental screening recommendations throughout their lives.

"We developed CancerIQ Reach with both the patient and the provider in mind," said Laku Adedoyin, Chief Technology Officer of CancerIQ. "This patient-enabled approach empowers patients with the right amount of information to take action at the right moment in their care journey, while enabling staff to maximize appointment time around shared decision making, rather than data collection."

This approach is proven to increase patient acquisition for high-value service lines, like imaging and oncology. For example, data from a pilot of CancerIQ Reach shows a campaign targeting patients with a history of smoking led to a 270% monthly increase in low-dose CT scans scheduled at the lung cancer screening clinic. Within the first two months of the campaign, four patients were diagnosed and successfully treated for Stage 1A lung cancer after LDCT screening. Further increasing systemwide value, the campaign led to a significant increase in referrals to radiology for breast MRIs, as well as several referrals to pulmonology and cardiology for follow-up care.

CancerIQ Reach is part of a broader solution for breast imaging and oncology that helps providers create and manage personalized, evidence-based care pathways over time based on comprehensive cancer risk, including genetic, hereditary, lifestyle, adherence risk factors.

For more information, please visit www.canceriq.com


Related Content

News | Artificial Intelligence

September 7, 2023 — Paige, a provider of end-to-end digital pathology solutions and clinical AI, has announced a ...

Time September 07, 2023
arrow
News | Radiology Business

July 27, 2023 — Privately-held biotech company TAE Life Sciences has announced that its board of directors has appointed ...

Time July 27, 2023
arrow
News | Interventional Radiology

Varian announced it has signed an asset purchase agreement to acquire the Boston Scientific portfolio of drug-loadable microsphere and bland embolic bead products for treating arteriovenous malformations and hypervascular tumors. When completed, this acquisition, in combination with the recent acquisitions of Endocare and Alicon, will expand Varian's portfolio of multidisciplinary integrated cancer care solutions.

Time July 03, 2019
arrow
Technology | Focused Ultrasound Therapy

Insightec announced that the U.S. Food and Drug Administration (FDA) has approved an expansion of the indication of Exablate Neuro to include the treatment of patients with tremor-dominant Parkinson's disease (PD).

Time December 21, 2018
arrow
Videos | Radiation Oncology

Genomics can be used to assess a patient's radiosensitivity, which can be used to increase or decrease the radiation ...

Time November 06, 2018
arrow
News | Radiation Dose Management

AngioDynamics Inc. announced an agreement to acquire RadiaDyne, a privately held medical diagnostic and device company that designs and develops patient dose monitoring technology to improve cancer treatment outcomes.

Time September 24, 2018
arrow
News | Radiation Oncology

World Cancer Day takes place annually on Feb. 4 to raise awareness and education in the media, governments and people ...

Time February 01, 2018
arrow
News | Oncology Related Products

December 19, 2016 — Children’s National Health System and Celsion Corp. announced in November the launch of a clinical ...

Time December 19, 2016
arrow
News | Clinical Decision Support

October 27, 2016 — The National Comprehensive Cancer Network (NCCN) continues to build its library of appropriate use ...

Time October 27, 2016
arrow
News | Ultrasound Imaging

September 12, 2016 — Tiny microbubbles are being used to more effectively identify liver tumors, according to a study ...

Time September 12, 2016
arrow
Subscribe Now